Department of Orthopaedic Surgery, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Department of Trauma Surgery, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Arch Orthop Trauma Surg. 2024 Dec;144(12):5177-5189. doi: 10.1007/s00402-024-05341-2. Epub 2024 May 1.
There is an increasing interest in the use of intra-articular (IA) antibiotic infusion as a stand-alone or adjuvant therapy to standard revision surgery for periprosthetic joint infection (PJI). The objective of this systematic review is to evaluate the evidence with respect to this up-and-coming treatment modality.
A systematic review of studies published until April 2023 was conducted using PubMed, Embase, MEDLINE and Cochrane databases. Quality assessment was performed with the National Institute of Health quality assessment tool. Inclusion criteria were adult patients (≥ 18 years) with a mean follow-up of ≥ 11 months and a score ≥ 6 on the National Institute of Health quality assessment tool. Primary outcome was eradication of infection.
15 articles, encompassing 631 PJIs in 626 patients, were included in the final analysis, all level IV case series. The majority was treated with single-stage revision with adjuvant IA antibiotic infusion (79.1%). The remaining PJIs were treated with stand-alone IA antibiotic infusion (12.2%), DAIR (debridement, antibiotics and implant retention) with adjuvant IA antibiotic infusion (5.7%) or two-stage revision with adjuvant IA antibiotic infusion (3.0%). Mean duration of IA antibiotic infusion was 19 days (range 3-50). An overall failure rate of approximately 11% was found. In total 117 complications occurred, 71 were non-catheter-related and 46 were catheter-related. The most common catheter-related complications were premature loss of the catheter (18/46) and elevated blood urea nitrogen (BUN) and creatinine levels (12/46).
Due to the lack of comparative studies the (added) benefit of IA antibiotic infusion in the treatment of PJI remains uncertain. Based on the current evidence, we would advise against using it as a stand-alone treatment. A prospective randomized controlled trial using a well-described infusion protocol is needed to see if the potential benefits justify the increased costs and potential complications of this treatment modality.
关节内(IA)抗生素输注作为一种单独或辅助标准翻修手术治疗人工关节周围感染(PJI)的方法,越来越受到关注。本系统评价的目的是评估这种新兴治疗方法的证据。
使用 PubMed、Embase、MEDLINE 和 Cochrane 数据库对截至 2023 年 4 月发表的研究进行了系统评价。使用美国国立卫生研究院质量评估工具进行质量评估。纳入标准为年龄≥18 岁的成人患者,平均随访时间≥11 个月,美国国立卫生研究院质量评估工具评分≥6。主要结局为感染消除。
最终分析纳入了 15 篇文章,共 626 例 631 例 PJI,均为 IV 级病例系列研究。大多数患者接受一期翻修联合辅助 IA 抗生素输注治疗(79.1%)。其余 PJI 采用单独 IA 抗生素输注(12.2%)、清创术、抗生素和保留植入物(DAIR)联合辅助 IA 抗生素输注(5.7%)或二期翻修联合辅助 IA 抗生素输注(3.0%)治疗。IA 抗生素输注的平均持续时间为 19 天(范围 3-50 天)。总体失败率约为 11%。共发生 117 例并发症,71 例与导管无关,46 例与导管相关。最常见的与导管相关的并发症是导管过早丢失(18/46)和血尿素氮(BUN)和肌酐水平升高(12/46)。
由于缺乏对照研究,IA 抗生素输注在治疗 PJI 中的(附加)益处仍不确定。根据目前的证据,我们不建议将其作为单独的治疗方法。需要进行前瞻性随机对照试验,使用描述良好的输注方案,以确定这种治疗方法的潜在益处是否证明增加的成本和潜在并发症是合理的。